Diversity and inclusion (D&I) are foundational to Lilly’s innovation business. We believe when we harness a variety of perspectives, it powers us to discover and deliver life-changing medicines.
While there’s more to do, we’re making progress. From the end of 2017 to the end of 2020, the percentage of Lilly management positions held by minorities in the United States and by women globally has increased from 16% to 22% and from 41% to 46%, respectively. Seven of 15 members (46%) of Lilly’s executive committee are women, including one who is a minority group member. The company's 15-member board of directors includes six women and seven members of underrepresented groups, including minority group members as well as lesbian, gay, bisexual, transgender or queer (LGBTQ) individuals. In 2020, we conducted in-depth research to understand the experience of Lilly’s LGBTQ employees, and we’re now taking action based on our research insights.
Lilly is committed to expanding our D&I efforts from our company to our communities. In 2020, Lilly launched a multifaceted Racial Justice Initiative to address racial injustices and to increase opportunities and equity for Black Americans. With local and national partnerships and investments, we’re developing solutions that drive meaningful progress. While we don’t claim to have all the answers, we do believe Lilly has a responsibility to take action on issues that affect our business, our employees and our communities.
Lilly's Diversity and Inclusion: By the Numbers
46%
Lilly global management positions held by women
27%
Lilly U.S. employees who are minorities
15
consecutive years Lilly has received a perfect score from the Human Rights Campaign
Our D&I Progress Report
Recognitions
Lilly Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s operations, results, business, goals and strategy may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes or developments in laws and regulations, including health care reform.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.
Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.